drugset
drugset / Trial / NCT04895709

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709 ↗

Phase 1/2 Recruiting 1109 enrolled Bristol-Myers Squibb
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.

Timeline

Start
2021-05-27
Primary completion
2031-08-31
Completion
2031-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule — —
Subject Imzokitug Monoclonal antibody — —
Subject Nivolumab Monoclonal antibody — —
Subject Pumitamig Protein / enzyme biologic — —

Indications

cervical cancer colorectal cancer gastroesophageal adenocarcinoma head and neck squamous cell carcinoma melanoma non-small cell lung carcinoma ovarian neoplasm pancreatic adenocarcinoma renal cell carcinoma triple-negative breast carcinoma urothelial carcinoma